A 55-Year-Old Man with Muscle-Invasive Bladder Cancer - Episode 3
Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.